Two new studies support use of PrEP for HIV prevention among heterosexual men and women

Published on July 14, 2011 at 8:16 AM · No Comments

"Two new studies done in three African countries have shown for the first time that AIDS drugs taken daily can cut by more than half a person's chance of becoming infected with HIV through heterosexual intercourse," the Washington Post reports. One of the studies, carried out in Kenya and Uganda by the University of Washington, was halted a year and a half early because of positive results, while the other, conducted in Botswana by the CDC, ended as scheduled in the spring, according to the newspaper (Brown, 7/13).

The larger study, funded by the Bill & Melinda Gates Foundation, involved 4,758 discordant couples in Kenya and Uganda, with the uninfected partners receiving either a placebo; the antiretroviral tenofovir, also called Viread; or a combination antiretroviral containing tenofovir and emtricitabine, called Truvada, the Associated Press/NPR reports. "The study found 13 HIV infections among those on Truvada, 18 in those on Viread, and 47 of those on dummy pills. So the medications reduced the risk of HIV infection by 62 percent to 73 percent, the researchers said," the news agency reports (7/13).

The other study involving "1,200 uninfected heterosexual men and women in Botswana found that those taking a once-daily dose of Truvada reduced their risk of acquiring HIV by about 63 percent compared to those taking a placebo. CDC researchers believe the results may be even stronger among participants who adhered closely to the regimen," according to the Wall Street Journal (Rockoff/McKay/Schoofs, 7/13).

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Dansk | Nederlands | Bahasa | Norsk | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment